Search

Your search keyword '"Zaccherini, Giacomo"' showing total 6 results
Start Over Author "Zaccherini, Giacomo" Journal gut
6 results on '"Zaccherini, Giacomo"'

1. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis

Author

Liu, Jinxia, primary, MacNaughtan, Jane, additional, Kerbert, Annarein J C, additional, Portlock, Theo, additional, Martínez Gonzalez, Javier, additional, Jin, Yi, additional, Clasen, Frederick, additional, Habtesion, Abeba, additional, Ji, Huoyan, additional, Jin, Qin, additional, Phillips, Alexandra, additional, De Chiara, Francesco, additional, Ingavle, Ganesh, additional, Jimenez, Cesar, additional, Zaccherini, Giacomo, additional, Husi, Katherine, additional, Rodriguez Gandia, Miguel Angel, additional, Cordero, Paul, additional, Soeda, Junpei, additional, McConaghy, Lynda, additional, Oben, Jude, additional, Church, Karen, additional, Li, Jia V, additional, Wu, Haifeng, additional, Jalan, Aarti, additional, Gines, Pere, additional, Solà, Elsa, additional, Eaton, Simon, additional, Morgan, Carrie, additional, Kowalski, Michal, additional, Green, Daniel, additional, Gander, Amir, additional, Edwards, Lindsey A, additional, Cox, I Jane, additional, Cortez-Pinto, Helena, additional, Avery, Thomas, additional, Wiest, Reiner, additional, Durand, Francois, additional, Caraceni, Paolo, additional, Elosua, Roberto, additional, Vila, Joan, additional, Pavesi, Marco, additional, Arroyo, Vicente, additional, Davies, Nathan, additional, Mookerjee, Rajeshwar P, additional, Vargas, Victor, additional, Sandeman, Susan, additional, Mehta, Gautam, additional, Shoaie, Saeed, additional, Marchesi, Julian, additional, Albillos, Agustín, additional, Andreola, Fausto, additional, and Jalan, Rajiv, additional

Published
2024
Full Text
View/download PDF

2. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.

Author

Jinxia Liu, MacNaughtan, Jane, Kerbert, Annarein J. C., Portlock, Theo, Gonzalez, Javier Martínez, Yi Jin, Clasen, Frederick, Habtesion, Abeba, Huoyan Ji, Qin Jin, Phillips, Alexandra, De Chiara, Francesco, Ingavle, Ganesh, Jimenez, Cesar, Zaccherini, Giacomo, Husi, Katherine, Rodriguez Gandia, Miguel Angel, Cordero, Paul, Soeda, Junpei, and McConaghy, Lynda

Subjects
HEPATORENAL syndrome, DIABETIC nephropathies, BETAINE, CIRRHOSIS of the liver, VITAMIN E, ANIMAL tracks, MEDICAL sciences
Published
2024
Full Text
View/download PDF

3. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.

Author

Juanola, Adrià, Ann Thu Ma, Koos de Wit, Gananandan, Kohilan, Roux, Olivier, Zaccherini, Giacomo, Jiménez, César, Tonon, Marta, Solé, Cristina, Villaseca, Clara, Uschner, Frank E., Graupera, Isabel, Pose, Elisa, Moreta, Maria José, Campion, Daniela, Beuers, Ulrich, Mookerjee, Rajeshawar P., Francoz, Claire, Durand, Francois, and Vargas, Victor

Subjects
HEPATORENAL syndrome, PROGNOSIS, CIRRHOSIS of the liver, HIGH mobility group proteins, ORGAN transplant waiting lists
Published
2024
Full Text
View/download PDF

4. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis

Author

Liu, Jinxia, MacNaughtan, Jane, Kerbert, Annarein J C, Portlock, Theo, Martínez Gonzalez, Javier, Jin, Yi, Clasen, Frederick, Habtesion, Abeba, Ji, Huoyan, Jin, Qin, Phillips, Alexandra, De Chiara, Francesco, Ingavle, Ganesh, Jimenez, Cesar, Zaccherini, Giacomo, Husi, Katherine, Rodriguez Gandia, Miguel Angel, Cordero, Paul, Soeda, Junpei, McConaghy, Lynda, Oben, Jude, Church, Karen, Li, Jia V, Wu, Haifeng, Jalan, Aarti, Gines, Pere, Solà, Elsa, Eaton, Simon, Morgan, Carrie, Kowalski, Michal, Green, Daniel, Gander, Amir, Edwards, Lindsey A, Cox, I Jane, Cortez-Pinto, Helena, Avery, Thomas, Wiest, Reiner, Durand, Francois, Caraceni, Paolo, Elosua, Roberto, Vila, Joan, Pavesi, Marco, Arroyo, Vicente, Davies, Nathan, Mookerjee, Rajeshwar P, Vargas, Victor, Sandeman, Susan, Mehta, Gautam, Shoaie, Saeed, Marchesi, Julian, Albillos, Agustín, Andreola, Fausto, and Jalan, Rajiv

Abstract

ObjectiveTargeting bacterial translocation in cirrhosis is limited to antibiotics with risk of antimicrobial resistance. This study explored the therapeutic potential of a non-absorbable, gut-restricted, engineered carbon bead adsorbent, Yaq-001 in models of cirrhosis and acute-on-chronic liver failure (ACLF) and, its safety and tolerability in a clinical trial in cirrhosis.DesignPerformance of Yaq-001 was evaluated in vitro. Two-rat models of cirrhosis and ACLF, (4 weeks, bile duct ligation with or without lipopolysaccharide), receiving Yaq-001 for 2 weeks; and two-mouse models of cirrhosis (6-week and 12-week carbon tetrachloride (CCl4)) receiving Yaq-001 for 6 weeks were studied. Organ and immune function, gut permeability, transcriptomics, microbiome composition and metabolomics were analysed. The effect of faecal water on gut permeability from animal models was evaluated on intestinal organoids. A multicentre, double-blind, randomised, placebo-controlled clinical trial in 28 patients with cirrhosis, administered 4 gr/day Yaq-001 for 3 months was performed.ResultsYaq-001 exhibited rapid adsorption kinetics for endotoxin. In vivo, Yaq-001 reduced liver injury, progression of fibrosis, portal hypertension, renal dysfunction and mortality of ACLF animals significantly. Significant impact on severity of endotoxaemia, hyperammonaemia, liver cell death, systemic inflammation and organ transcriptomics with variable modulation of inflammation, cell death and senescence in the liver, kidneys, brain and colon was observed. Yaq-001 reduced gut permeability in the organoids and impacted positively on the microbiome composition and metabolism. Yaq-001 regulated as a device met its primary endpoint of safety and tolerability in the clinical trial.ConclusionsThis study provides strong preclinical rationale and safety in patients with cirrhosis to allow clinical translation.Trial registration numberNCT03202498.

Published
2024
Full Text
View/download PDF

5. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

Author

Weiss, Emmanuel, primary, de la Peña-Ramirez, Carlos, additional, Aguilar, Ferran, additional, Lozano, Juan-Jose, additional, Sánchez-Garrido, Cristina, additional, Sierra, Patricia, additional, Martin, Pedro Izquierdo-Bueno, additional, Diaz, Juan Manuel, additional, Fenaille, François, additional, Castelli, Florence A, additional, Gustot, Thierry, additional, Laleman, Wim, additional, Albillos, Agustín, additional, Alessandria, Carlo, additional, Domenicali, Marco, additional, Caraceni, Paolo, additional, Piano, Salvatore, additional, Saliba, Faouzi, additional, Zeuzem, Stefan, additional, Gerbes, Alexander L, additional, Wendon, Julia A, additional, Jansen, Christian, additional, Gu, Wenyi, additional, Papp, Maria, additional, Mookerjee, Raj, additional, Gambino, Carmine Gabriele, additional, Jiménez, Cesar, additional, Giovo, Ilaria, additional, Zaccherini, Giacomo, additional, Merli, Manuela, additional, Putignano, Antonella, additional, Uschner, Frank Erhard, additional, Berg, Thomas, additional, Bruns, Tony, additional, Trautwein, Christian, additional, Zipprich, Alexander, additional, Bañares, Rafael, additional, Presa, José, additional, Genesca, Joan, additional, Vargas, Victor, additional, Fernández, Javier, additional, Bernardi, Mauro, additional, Angeli, Paolo, additional, Jalan, Rajiv, additional, Claria, Joan, additional, Junot, Christophe, additional, Moreau, Richard, additional, Trebicka, Jonel, additional, and Arroyo, Vicente, additional

Published
2023
Full Text
View/download PDF

6. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.

Author

Juanola A, Ma AT, de Wit K, Gananandan K, Roux O, Zaccherini G, Jiménez C, Tonon M, Solé C, Villaseca C, Uschner FE, Graupera I, Pose E, Moreta MJ, Campion D, Beuers U, Mookerjee RP, Francoz C, Durand F, Vargas V, Piano S, Alonso S, Trebicka J, Laleman W, Asrani SK, Soriano G, Alessandria C, Serra-Burriel M, Morales-Ruiz M, Torres F, Allegretti AS, Krag A, Caraceni P, Watson H, Abraldes JG, Solà E, Kamath PS, Hernaez R, and Ginès P

Subjects
Humans, Prognosis, Prospective Studies, Interleukin-6, Severity of Illness Index, Biomarkers, Liver Cirrhosis complications, End Stage Liver Disease
Abstract

Background: Patients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were initially developed. Novel biomarkers have been proposed to improve prognostication accuracy and even to predict development of complications., Methods: We performed a systematic review and meta-analysis on novel urine and blood biomarkers and their ability to predict 90-day mortality in patients with decompensated cirrhosis. Secondary outcomes included 28-day and 1-year mortality, and development of acute-on-chronic liver failure, acute kidney injury and other complications. To overcome differences in units, temporal changes in assays and reporting heterogeneity, we used the ratio of means (RoM) as measure of association for assessing strength in predicting outcomes. An RoM>1 implies that the mean biomarker level is higher in those that develop the outcome than in those that do not., Results: Of 6629 unique references, 103 were included, reporting on 29 different biomarkers, with a total of 31 362 biomarker patients. Most studies were prospective cohorts of hospitalised patients (median Child-Pugh-Turcotte score of 9 and MELD score of 18). The pooled 90-day mortality rate was 0.27 (95% CI 0.24 to 0.29). The RoM for predicting 90-day mortality was highest for interleukin 6 (IL-6) (2.56, 95% CI 2.39 to 2.74), followed by urinary neutrophil gelatinase-associated lipocalin (uNGAL) (2.42, 95% CI 2.20 to 2.66) and copeptin (2.33, 95% CI 2.17 to 2.50). These RoMs were all higher than for MELD (1.44, 95% CI 1.42 to 1.46)., Conclusion: Novel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone., Competing Interests: Competing interests: FD consults for Biotest. VV consults for Promethera and is on the speakers bureau for Intercept. SP advises Mallinckrodt. HW is employed by Evotec and owns stock in Sanofi. PG consults for and received grants from Gilead, Grifols and Mallinckrodt, and consults for Novartis, Martin and Ferring. JT has received speaking and/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Falk, Grifols, Genfit and CSL Behring. RH is part of the Editorial Board of the Gut journal., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results